Intention-to-treat analysis demonstrated that patientsin the active treatment group achieved a lower BP—onaverage a 15 mmHg lower systolic BP and a 6 mmHglower diastolic BP over the 1.8 years of the study. Thistranslated into a non-significant 30% reduction inthe primary end-point of all stroke (P=0.055), but asignificant 39% reduction in fatal stroke (P=0.046), a21% reduction in total mortality (P=0.019) and a 64%reduction in the incidence of heart failure (P<0.0001).A pre-specified analysis of patients who remained ondouble-blind treatment for the course of the studydemonstrated significant reductions in the primary endpointand all secondary end-points. From HYVET, it wasconcluded that treatment of the very elderly with antihypertensivetherapy with a BP target of 150/80 mmHgwas beneficial and that the treatment regimen usedwas safe and effective (Becket et al, 2008). However,when interpreting these results for clinical practice, it isimportant to note that the participants in HYVET weregenerally healthier that those in the general populationof the same age.Treatment guidelinesData from HYVET had a significant influence ofNICE’s (2011) guidelines on the clinical management ofhypertension in adults (CG127). A new BP treatmenttarget of 150/90 mmHg was set for this older cohort ofpeople in view of the evidence of benefit (NICE, 2011).However, there remains no evidence to support a moreaggressive treatment target in the older group of patients.Similarly, the 2011 American College of CardiologyFoundation (ACCF) Task Force and 2013 ESH/ESCguidelines recommend a systolic BP goal of 140–150 mmHg in patients older than 80 years (Aronowet al, 2011; Mancia et al, 2013). In patients youngerthan 80 years, a systolic BP less than 140 mmHg can beconsidered. In the fragile elderly population, systolic BPgoals should be adapted to individual tolerabilityas aggressive treatment can have adverse outcomes(Mancia et al, 2013).
การแปล กรุณารอสักครู่..
